Business Description
Crinetics Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US22663K1079
Description
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 16.42 | |||||
| Equity-to-Asset | 0.89 | |||||
| Debt-to-Equity | 0.06 | |||||
| Debt-to-EBITDA | -0.17 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 29.26 | |||||
| Beneish M-Score | -3.34 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -16.2 | |||||
| 3-Year EPS without NRI Growth Rate | -15.1 | |||||
| 3-Year FCF Growth Rate | -13 | |||||
| 3-Year Book Growth Rate | 15.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate | -6.34 | |||||
| Future 3-5Y Total Revenue Growth Rate | 113.02 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 55.1 | |||||
| 9-Day RSI | 51.75 | |||||
| 14-Day RSI | 51.75 | |||||
| 6-1 Month Momentum % | 22.81 | |||||
| 12-1 Month Momentum % | 75.65 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 16.38 | |||||
| Quick Ratio | 16.38 | |||||
| Cash Ratio | 16.11 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -27.4 | |||||
| Shareholder Yield % | -9.26 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -29525.22 | |||||
| Net Margin % | -26747.83 | |||||
| FCF Margin % | -19592.01 | |||||
| ROE % | -38.33 | |||||
| ROA % | -33.66 | |||||
| ROIC % | -351.41 | |||||
| ROC (Joel Greenblatt) % | -536.13 | |||||
| ROCE % | -39.49 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 4085.71 | |||||
| PB Ratio | 5.55 | |||||
| Price-to-Tangible-Book | 5.55 | |||||
| EV-to-EBIT | -14.65 | |||||
| EV-to-EBITDA | -14.76 | |||||
| EV-to-Revenue | 4325.76 | |||||
| EV-to-Forward-Revenue | 688.86 | |||||
| EV-to-FCF | -22.08 | |||||
| Price-to-Net-Current-Asset-Value | 5.98 | |||||
| Price-to-Net-Cash | 6.1 | |||||
| Earnings Yield (Greenblatt) % | -6.83 | |||||
| FCF Yield % | -3.84 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CRNX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Crinetics Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1.039 | ||
| EPS (TTM) ($) | -3.73 | ||
| Beta | -0.14 | ||
| Volatility % | 26.98 | ||
| 14-Day RSI | 51.75 | ||
| 14-Day ATR ($) | 2.159528 | ||
| 20-Day SMA ($) | 57.4415 | ||
| 12-1 Month Momentum % | 75.65 | ||
| 52-Week Range ($) | 31.62 - 62.53 | ||
| Shares Outstanding (Mil) | 92.74 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Crinetics Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Crinetics Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Crinetics Pharmaceuticals Inc Frequently Asked Questions
What is Crinetics Pharmaceuticals Inc(CRNX)'s stock price today?
The current price of CRNX is $57.20. The 52 week high of CRNX is $62.53 and 52 week low is $31.62.
When is next earnings date of Crinetics Pharmaceuticals Inc(CRNX)?
The next earnings date of Crinetics Pharmaceuticals Inc(CRNX) is 2025-02-28 Est..
Does Crinetics Pharmaceuticals Inc(CRNX) pay dividends? If so, how much?
Crinetics Pharmaceuticals Inc(CRNX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers